Endocrine Abstracts

Introduction: In clinical trials, dapagliflozin has been shown to lower blood glucose, reduce weight and blood pressure in people with type 2 diabetes (T2D). However, there are limited published data on quantitative changes on blood pressure of this drug in routine clinical practice. Our aim was to examine the clinical efficacy of dapagliflozin in patients with T2D and hypertension in a real-life cohort.

Methods/design: Prospective study including patients with poorly controlled T2D and hypertension who were added dapagiflozin in conditions of routine medical practice. Metabolic profile, renal parameters and hemodynamic parameters were measured prior to dapagliflozin intensification and at week 24.

Results: 16 patients were evaluated. At week 24, urine volume increased from 1761±693.6 ml/day to 2570.83±758.6 ml/day; P<0.001 as well as natriuresis (from 211.6±73.7 mEq/day at baseline to 252.8±94.5 mEq/day; p=0.009). No significant differences were observed in eGFR and albumin/creatinine ratio. Systolic blood pressure significantly decreased from baseline (148.9±20.8 vs 141.5±17.9; P=0.02) as well as diastolic blood pressure (84.3±11.9 vs 78.8±8.9: P=0.001). In five patients, variability of blood pressure was measured showing a significant reduction (15.2±1.9 vs 10.4±2.1; P=0.02).

Conclusions: Our results show a higher decrease in blood pressure that observed in clinical trials. Dapagliflozin might potentially improve not only the average blood pressure, but also reduces its variability. We included a little number of patients. Further investigations are needed to verify our observation and determine its potential role on cardiovascular outcomes.